期刊
NUTRIENTS
卷 15, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/nu15030578
关键词
24; 25-dihydroxy vitamin D; 25-hydroxyvitamin D; vitamin D metabolite ratio; chronic kidney disease
Appropriate management of vitamin D deficiency and hyperparathyroidism is essential in preventing metabolic bone disorder and cardiovascular diseases in chronic kidney disease. The study found that the ratio of 24,25-dihydroxyvitamin D to 25-hydroxyvitamin D (VMR) can serve as a useful biomarker for evaluating metabolic bone disorder in CKD patients. The study concluded that 24,25-dihydroxyvitamin D and VMR have the potential to be reliable vitamin D biomarkers in CKD patients.
The appropriate management of vitamin D deficiency and hyperparathyroidism is essential to prevent metabolic bone disorder (MBD) and cardiovascular diseases in chronic kidney disease (CKD). Recently, the 24,25-dihydroxyvitamin D [24,25(OH)(2)D] and vitamin D metabolite ratio (VMR), i.e., the ratio of 24,25(OH)(2)D to 25-hydroxyvitamin D [25(OH)D], have emerged as biomarkers of vitamin D level. We analyzed the usefulness of vitamin D biomarkers for the evaluation of MBD in patients with CKD. We analyzed blood and urine samples from 208 outpatients with CKD stage G2-G5. 25(OH)D showed a poor correlation with the estimated glomerular filtration rate (eGFR). Conversely, the 24,25(OH)(2)D level and VMR were significantly correlated with eGFR and the intact parathyroid hormone level. In conclusion, 24,25(OH)(2)D and VMR have the potential to be vitamin D biomarkers for the detection of MBD in CKD patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据